IPSEN SA SP.ADR 1/4/ EO 1 Total Assets
IPSEN SA SP.ADR 1/4/ EO 1 total assets. Based on the latest financial reports, IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) holds total assets worth €6.94 Billion EUR (≈ $8.11 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of IPSEN SA SP.ADR 1/4/ EO 1 for the company's overall valuation and market capitalisation.
Total Assets of IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
Total assets of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025. This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's total assets have evolved over time, based on quarterly financial data. See IPSEN SA SP.ADR 1/4/ EO 1 stock price for real-time trading data and today's change.
IPSEN SA SP.ADR 1/4/ EO 1 - Asset Composition Analysis
IPSEN SA SP.ADR 1/4/ EO 1 Total Assets Breakdown (December 2025)
IPSEN SA SP.ADR 1/4/ EO 1 total assets breakdown as of December 2025. IPSEN SA SP.ADR 1/4/ EO 1's total assets of €6.94 Billion consist of 40.7% current assets and 59.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.0% |
| Accounts Receivable | €786.80 Million | 11.3% |
| Inventory | €240.90 Million | 3.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.29 Billion | 33.0% |
| Goodwill | €633.80 Million | 9.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IPSEN SA SP.ADR 1/4/ EO 1's current assets represent 40.7% of total assets in 2025, an increase from 39.2% in 2021.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2025, up from 16.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 39.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.0% of total assets.
IPSEN SA SP.ADR 1/4/ EO 1 Competitors by Total Assets
Key competitors of IPSEN SA SP.ADR 1/4/ EO 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
IPSEN SA SP.ADR 1/4/ EO 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 1.34 | 1.34 |
| Quick Ratio | 1.79 | 1.15 | 1.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.38 Billion | €515.80 Million | €515.80 Million |
IPSEN SA SP.ADR 1/4/ EO 1 - Advanced Valuation Insights
This section examines the relationship between IPSEN SA SP.ADR 1/4/ EO 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.18 |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | €6.94 Billion |
| Market Capitalization | $12.92 Billion USD |
Valuation Analysis
Above Book Valuation: The market values IPSEN SA SP.ADR 1/4/ EO 1's assets above their book value (1.86x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: IPSEN SA SP.ADR 1/4/ EO 1's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual total assets of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €6.94 Billion ≈ $8.11 Billion |
+7.75% |
| 2024-12-31 | €6.44 Billion ≈ $7.53 Billion |
+1.84% |
| 2023-12-31 | €6.32 Billion ≈ $7.39 Billion |
+12.62% |
| 2022-12-31 | €5.61 Billion ≈ $6.56 Billion |
+12.51% |
| 2021-12-31 | €4.99 Billion ≈ $5.83 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more